Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase NA 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 174Myeloid 64Lymphoid 28Thoracic 7Gastrointestinal 5Classical hematology 5Breast 4Plasma cell 3Genitourinary 3Sarcoma 2Head & Neck 2Gynecologic 2Dermatologic 1CNS 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Microsatellite Stable Colorectal Carcinoma 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 347Paclitaxel 309Cyclophosphamide 286Docetaxel 267Carboplatin 215Capecitabine 214Letrozole 185Fulvestrant 176Doxorubicin 166Bevacizumab 136Anastrozole 120Tamoxifen 117pertuzumab 112pembrolizumab 112Epirubicin 110exemestane 107Vinorelbine 106Gemcitabine 106Albumin-Bound Paclitaxel 92Lapatinib 84130-nm albumin-bound paclitaxel 83Radiotherapy 79palbociclib 75eribulin 73Cisplatin 69pyrotinib 65Taxes 65Everolimus 55Goserelin 50Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Azacitidine × Breast × Clear all
NCT04891068 2026-01-14

BRE-04

University of Illinois at Chicago

Phase 2 Recruiting
40 enrolled
Breast

Breast Neoplasms

NCT01349959 2025-04-27

Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
58 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT02811497 2021-04-01

METADUR

University Health Network, Toronto

Phase 2 Completed
28 enrolled
BreastGastrointestinalGynecologic

Microsatellite Stable Colorectal Carcinoma

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Celgene

Phase 2 Terminated
97 enrolled 18 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡